Microphysiological Systems for Cell-Therapy Pharmacokinetics: Current Insights and Clinical Implications

Abstract

Microphysiological systems (MPS), also known as organs-on-chips, have emerged as transformative platforms for studying cell-therapy pharmacokinetics (PK). By recapitulating human tissue microenvironments and physiological responses, MPS provide a bridge between in vitro and in vivo models, addressing key translational gaps in cell-based therapy development. This review consolidates current scientific evidence on the utility of MPS for cell-therapy PK, highlighting their role in elucidating dynamic cellular interactions, biodistribution, and therapeutic efficacy. The article further explores epidemiological needs, mechanism-based insights, clinical relevance, and recent advances, offering practical recommendations for healthcare professionals and researchers.

Introduction

The field of cell-based therapies has rapidly advanced, with applications ranging from hematological malignancies to regenerative medicine. However, the complex in vivo behavior of therapeutic cells poses significant challenges for pharmacokinetic (PK) modeling, limiting the predictability and safety profile of these interventions. Traditional preclinical models often fail to recapitulate human-specific responses, necessitating innovative platforms that can bridge this translational gap. Microphysiological systems (MPS), encompassing tissue-engineered organoids and organs-on-chips, have emerged as robust tools for modeling human physiology and disease, offering unprecedented opportunities for investigating cell-therapy PK, efficacy, and safety.

Epidemiology / Disease Burden

The global burden of diseases amenable to cell-based therapies, such as hematological cancers, heart failure, and autoimmune disorders, continues to rise. For example, the incidence of acute lymphoblastic leukemia and relapsed/refractory non-Hodgkin lymphoma remains significant, with thousands of new cases annually requiring advanced treatment. Despite the clinical promise of chimeric antigen receptor (CAR) T-cell therapies and stem cell interventions, a substantial proportion of patients experience suboptimal responses or adverse events related to unpredictable cell kinetics and biodistribution, underscoring the need for improved preclinical modeling.

Pathophysiology

Cell therapies act through complex mechanisms involving targeted cell homing, expansion, and functional modulation within recipient tissues. These processes are governed by cell-intrinsic properties, tissue microenvironmental cues, and systemic factors such as immunogenicity and cytokine milieu. PK parameters absorption, distribution, metabolism, and excretion (ADME) for cell therapies are influenced by trafficking patterns, niche retention, and survival rates, which standard animal models inadequately capture due to interspecies differences. MPS provide a unique solution by mimicking human pathophysiology, including vascular, stromal, and immune interactions, allowing for mechanistic dissection of cell therapy fate in a controlled, tunable environment.

Risk Factors

Several factors impact cell-therapy PK and outcomes, including patient-specific variables (age, immune status, comorbidities), cell product characteristics (source, expansion method, genetic modification), and disease-related factors (tumor microenvironment, tissue fibrosis). Risk stratification is complicated by the lack of predictive biomarkers and the limitations of conventional preclinical models. MPS enable stratified experimentation by incorporating patient-derived cells, variable tissue constructs, and real-time monitoring, thereby facilitating the identification of risk modifiers and optimizing therapy design.

Clinical Features

The clinical manifestations of cell therapies are intimately linked to their pharmacokinetic profiles. Early expansion and persistence of therapeutic cells correlate with response rates in CAR T-cell therapy, while poor engraftment or aberrant trafficking is associated with failure or toxicity, such as cytokine release syndrome (CRS) and off-target effects. MPS allow detailed observation of these events, including cell migration, tissue infiltration, and interaction with host cells, providing actionable insights for improving clinical outcomes.

Diagnosis

Monitoring cell-therapy PK in patients is challenging, typically relying on peripheral blood sampling, imaging, and biomarker analyses, which offer limited spatial and temporal resolution. MPS facilitate the integration of advanced diagnostic modalities, such as live-cell imaging, biosensors, and multiplexed assays, within physiologically relevant human tissue contexts. These innovations enhance the granularity of PK assessments and support the development of more sensitive and predictive diagnostic tools.

Treatment & Management

Optimal management of cell therapies requires precise understanding of PK to inform dosing, scheduling, and supportive care. MPS-based models enable preclinical optimization by simulating various dosing regimens, cell modifications, and combinatorial strategies under human-like physiological conditions. Insights gained from MPS studies have informed clinical protocols, such as fractionated dosing in CAR T-cell therapy to mitigate toxicity, and have accelerated the translation of novel cell products into clinical trials.

Recent Advances / Emerging Therapies

Recent developments in MPS technology include multi-organ-on-chip platforms, immune-on-chip models, and patient-specific constructs derived from induced pluripotent stem cells (iPSCs). These advances capture inter-organ crosstalk, immune interactions, and patient heterogeneity, enhancing the predictive validity of PK studies. Emerging therapies, such as gene-edited immune cells and tissue-engineered grafts, are being evaluated in MPS to elucidate biodistribution, persistence, and potential off-target effects prior to clinical application, streamlining regulatory approval and de-risking development pipelines.

Guideline Recommendations

Regulatory bodies and expert panels increasingly endorse the integration of MPS into the preclinical evaluation of cell therapies. The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) recommend leveraging human-relevant models to support investigational new drug (IND) applications and inform risk assessments. Clinical guidelines now recognize the potential of MPS to refine PK predictions, improve patient stratification, and enhance safety monitoring, advocating for collaborative research and standardization of MPS platforms in cell-therapy development.

Conclusion

Microphysiological systems represent a paradigm shift in the preclinical assessment of cell-therapy pharmacokinetics, providing mechanistic insights, predictive power, and translational relevance beyond conventional models. By recapitulating human tissue architecture and function, MPS facilitate the rational design, optimization, and personalized application of cell-based therapies. Ongoing advances in MPS technology, coupled with regulatory support and clinical integration, are poised to accelerate the safe and effective implementation of next-generation cell therapies for diverse patient populations.